Hemopericardium has occurred secondary to hemorrhagic myocarditis and myocardial necrosis. Pericarditis has been reported independent of any hemopericardium . No residual cardiac abnormalities, as evidenced by electrocardiogram or echocardiogram appear to be present in patients survivi ng episodes of apparent cardiac toxicity associated with high doses of cyclophosphamide.Cyclophosphamide has been reported to potentiate doxorubicin-induced cardiotoxicity.Protocol ADU-CL-02-v8Aduro Biotech, Inc. CRS-207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 124 page 3 of 9Infections Treatment with cyclophosphamide may cause significant suppression of immune responses. Serious, sometimes fatal, infections may develop in severely immunosuppressed patients. Cyclophosphamide treatment may not be indicated, or should be interrupted, or th e dose reduced, in patients who have or who develop viral, bacterial, fungal, protozoan, or helminthic infections. Other Anaphylactic reactions have been reported; death has also been reported in association with this event. Possible cross-sensitiv ity with other alkylating agents has been reported. PRECAUTIONS General Special attention to the possible development of toxicity should be exercised in patients being treated with cyclophosphamide i f any of the following conditions are present. 1.